Treatment of Down's Syndrome With the "U" Series of Drugs

Bumbalo, Thomas S.; Morelewicz, Henry V.; Berens, David L.

doi:10.1001/jama.1964.03060180047015

Cited by 15 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, their sample size was only five in the active treatment group and 11 in the control group; the groups were not determined by random allocation and were inadequately matched for sex and age. A later stratified study (Smith et al 1984) of 56 Down children, using vitamins and minerals as proposed by Harrell and colleagues, and other comparable studies on supplementary diets (Bumbalo et al 1964, Turkel 1975, Pueschel 1981), failed to show benefit. Nevertheless, parents continue to demand high-dosage vitamin/mineral preparations, still believing that they benefit their children.…”

mentioning

confidence: 95%

The Effectsof Multivitamins and Minerals on Children With Down Syndrome

Bidder

Gray

Newcombe

et al. 1989

Develop Med Child Neuro

View full text Add to dashboard Cite

SUMMARY The effects of high‐dosage multivitamin and mineral supplements on 15 children with Down syndrome aged between 7‐5 and 63 months were studied in a placebo‐controlled crossover trial. Active treatment was associated with decreased developmental progress, and various side‐effects were reported by the parents. The only suggestions of benefit were parents' observations of improvement in general appearance and skin freshness. However, the parents were willing to continue using the treatment and to recommend it to other parents, despite the side‐effects. RÉSUMÉ Effets de multivitamines et oligo‐éléments chez le mongolien Les effets de multivitamines à haute dose et compléments d'oligo‐éiéments chez 15 mongoliens âgés de 7,5 à 63 mois, ont étéétudiés dans un essai avec contrôle placébo et experience croisée. La poursuite du traitement fut associéà une diminution de la vitesse de développement et des effets secondares variés furent signalés par les parents. La seule possibilité de progrès a été l'observation des parents concernant une amélioration de Papparence générate et de l'aspect de la peau. Cependant, les parents ont été désireux de poursuivre le traitement et de le recommander à d'autres parents, en dépit des effets indésirables. ZUSAMMENFASSUNG Die Wirkung von Multivitaminen und Mineralien bei Kindern mit Down‐Syndrom Bei 15 Kindern mit Down‐Syndrom im Alter zwischen 7·5 und 63 Monaten wurde in einer Placebo kontrollierten Kreuzstudie die Wirkung von hochdosierten Multivitamin‐ und Mineraliensubstitutionen untersucht. Wáhrend der Substitutionstherapie fand sich ein verminderter Entwicklungsfortschritt und die Eltern berichteten über verschiedene Nebenwirkungen. Der einzige positive Effekt bestand darin, daß die Eltern eine Besserung des allgemeinen Aussehens und der Hautfrische bemerkten. Die Eltern waren dennoch gewillt, die Therapie trotz der Nebenwirkungen fortzusetzen und anderen Eltern zu empfehlen. RESUMEN Efecto de multivitaminas y minerales en niños con sindrome de Down En un ensayo cruzado controlado con placebo se estudiaron los efectos de suplementos de altas dosis de multivitaminas y minerales en 15 niños con sindrome de Down de edad entre 7·5 y 63 meses. El tratamiento activo se asoció a úna disminución del progreso de desarrollo y los padres mencionaron diversos efectos secundarios. La única sugerencia de algiin beneficio fue la observacion de los padres acerca de la mejora en el aspecto general y frescor de la piel. Sin ambargo los padres querian seguir el tratamiento y recomendarlo a otros padres a pesar de los efectos secundarios.

show abstract

mentioning

confidence: 95%

The Effectsof Multivitamins and Minerals on Children With Down Syndrome

Bidder

Gray

Newcombe

et al. 1989

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…One study comparing "U" series with placebo included 24 children with DS 3 months to 11 years of age. No differences were found in the parameters measured, including IQ on the Stanford-Binet, growth, hemogram, urinalysis, or X-rays between the groups receiving placebo and "U" therapy [Bumbalo et al, 1964]. In 1981, in an uncontrolled and unblinded study, Harrell et al [1981] reported that supplementary vitamins, minerals, and thyroid hormone improved IQ scores and caused "physical changes towards normal" among children with various types of mental deficiency with the best results in three children with DS.…”

mentioning

confidence: 98%

Complementary and alternative therapies for Down syndrome

Roizen

2005

Ment. Retard. Dev. Disabil. Res. Rev.

View full text Add to dashboard Cite

In their role as committed advocates, parents of children with Down syndrome have always sought alternative therapies, mainly to enhance cognitive function but also to improve their appearance. Nutritional supplements have been the most frequent type of complementary and alternative therapy used. Cell therapy, plastic surgery, hormonal therapy, and a host of other therapies such as massage therapy have been used. There is a lack of well-designed scientific studies on the use of alternative therapies in individuals with Down syndrome. Antioxidants hold theoretical promise for treatment of the cognitive, immune, malignancy, and premature aging problems associated with Down syndrome. Medications for treatment of Alzheimer's disease may also result in benefit for the population of individuals with Down syndrome.

show abstract

“…While Turkel did not present data from wellcontrolled studies, he provided several case studies to support his claims. However, when the ''U'' series was independently evaluated, with Turkel providing the ''U'' series as well as placebo, no improvement in the experimental subjects over controls was found [Bumbalo et al, 1964]. Although the ''U'' series is reportedly used extensively in other countries, such as Japan and Norway [Turkel et al, 1984], it was never approved by the Food and Drug Administration (FDA) for use in the United States.…”

Section: The ''U'' Series Treatmentmentioning

confidence: 96%